Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Söderåkra Cardiovascular Risk Factor Study

Diabetes and Metabolism

Volumn 35, Issue 3, 2009, Pages 198-205

  Petersson, U ^a,b   Ostgren C J ^b   Brudin, L ^b   Brismar, K ^c   Nilsson, P M ^d  

^a Kalmar County Council   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

CRP; IGFBP 1; Longitudinal study; Prediction; Screening; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ABDOMINAL OBESITY; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK; WAIST CIRCUMFERENCE;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MIDDLE AGED; RISK FACTORS; SWEDEN;

EID: 67349108377     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.11.003     Document Type: Article

References (35)

1. Baxter R.C. Insulin-like growth factor binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 65 (2000) 432-440
2. Heald A.H., Cruickshank J.K., Riste L.K., Cade J.E., Anderson S., Greenhalgh A., et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44 (2001) 333-339
3. Harrela M., Koistinen R., Tuomilehto J., Nissinen A., and Seppala M. Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med 32 (2000) 424-428
4. Gibson J.M., Westwood M., Young R.J., and White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin-dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 81 (1996) 860-863
5. Janssen J.A., Stolk R.P., Pols H.A., Grobbee D.E., and Lamberts S.W. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 18 (1998) 277-282
6. Lemne C., and Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome - a study in borderline hypertension. Blood Press 7 (1998) 89-95
7. Rajaram S., Baylink D.J., and Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18 (1997) 801-831
8. Grant M., Jerdan J., and Merimee T.J. Insulin-like growth factor-I modulates endothelial cell chemotaxis. J Clin Endocrinol Metab 65 (1987) 370-371
9. Gockerman A., Prevette T., Jones J.I., and Clemmons D.R. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I. Endocrinology 136 (1995) 4168-4173
10. Mohan S., and Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175 (2002) 19-31
11. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
12. Frystyk J., Hojlund K., Rasmussen K., Jorgensen S.P., Wildner-Christensen M., et al. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein-1 in human serum. J Clin Endocrinol Metab 87 (2002) 260-266
13. Benbassat C.A., Maki K.C., and Unterman T.G. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 82 (1997) 1484-1491
14. Nystrom F.H., Ohman P.K., Ekman B.A., Osterlund M.K., Karlberg B.E., and Arnqvist H.J. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol 136 (1997) 165-172
15. Hong Y., Pedersen N.L., Brismar K., Hall K., and de Faire U. Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 81 (1996) 1791-1797
16. Hong Y., Brismar K., Hall K., Pedersen N.L., and de Faire U. Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J Endocrinol 153 (1997) 251-257
17. Wolk K., Larsson S.C., Vessby B., Wolk A., and Brismar K. Metabolic, anthropometric and nutritional factors as predictors of circulating insulin-like growth factor binding protein-1 levels in middle-aged and elderly men. J Clin Endocrinol Metab 89 (1997) 1879-1884
18. Sandhu M.S., Heald A.H., Gibson J.M., Cruickshank J.K., Dunger D.B., and Wareham N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359 (2002) 1740-1745
19. Undén A.L., Elofsson S., and Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors. A population-based study. Clin Endocrinol 63 (2005) 94-102
20. Petersson U., and Kjellstrom T. Thyroid function tests, serum lipids and gender interrelations in a middle-aged population. Scand J Prim Health Care 19 (2001) 183-185
21. Bang P., Eriksson U., Sara V., Wivall I.L., and Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 124 (1991) 620-629
22. Póvoa G., Roovete A., and Hall K. Cross reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 107 (1984) 563-570
23. Paassilta M. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal oestrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 149 (2000) 157-162
24. Cardim H.J., Lopes C.M., Giannella-Neto D., da Fonseca A.M., and Pinotti J.A. The insulin-like growth factor-I system and hormone replacement therapy. Fertil Steril 75 (2001) 282-287
25. World Health Organization. Diabetes mellitus: report of a WHO study group. Geneva: WHO, 1985, technical report series 727.
26. Alberti K.G.M.M., and Zimmet. Pl for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Diabet Med 15 (1998) 539-553
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
28. Nilsson P.M., Engstrom G., and Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects - a population-based study comparing three different definitions. Diabet Med 24 (2007) 464-472
29. D'Orazio P., Burnett R.W., Fogh-Andersen N., Jacobs E., Kuwa K., Külpmann W.R., et al. Approved IFCC recommendation on reporting results for blood glucose: international federation of clinical chemistry and laboratory medicine scientific division. Working group on selective electrodes and point-of-care testing (IFCC-SD-WG-SEPOCT). 1. Clin Chem Lab Med 44 (2006) 1486-1490
30. Mogul H.R., Marshall M., Frey M., Burke H.B., Wynn P.S., Wilker S., et al. Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 81 (1996) 4492-4495
31. Saitoh H., Kamoda T., Nakahara S., Hirano T., and Matsul A. Insulin-like growth factor binding protein-1 as a predictor of glucose-stimulated hyperinsulinemia in prepubertal obese children. Eur J Endocrinol 140 (1999) 231-234
32. Brismar K., Grill V., Efendic S., and Hall K. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 40 (1991) 728-732
33. Venugopal S.K., Devaraj S., and Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 14 (2005) 33-37
34. Dehghan A., van Hoek M., Sijbrands E.J., Stijnen T., Hofman A., and Witteman J.C. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care 30 (2007) 2695-2699
35. Lewitt M.S., Hilding A., Ostenson C.G., Efendic S., Brismar K., and Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 51 (2008) 1135-1145